腮腺睾丸核蛋白癌1例病例报告

doi:10.3969/j.issn.1005-4979.2021.03.014

摘要/Abstract

摘要：

睾丸核蛋白（nuclear protein of the testis， NUT）癌是一种罕见的高度侵袭性恶性肿瘤,通常发生于中线部位，多发生于头颈部。镜下具有独特的组织病理学表现。免疫组织化学及荧光原位杂交（fluorescence in situ hybridization,FISH）结果均显示为NUT（+）。本文对1例腮腺NUT癌的临床病理特征、诊断、治疗及鉴别诊断进行简要分析，探讨目前头颈部NUT癌的诊断、治疗及预后。

关键词: 睾丸核蛋白癌, 头颈部, 腮腺, 诊断, 预后

Abstract:

Nuclear protein of the testis(NUT) carcinoma is a rare and aggressive carcinoma that typically arises from midline structures, frequently from the head and neck area. Under microscope, it has special histopathological manifestations. Immunohistochemistry and fluorescence in situ hybridization(FISH) showed that NUT（+）. This article briefly analyzes the clinicopathological characteristics, diagnosis, treatment and differential diagnosis of a case of NUT carcinoma of the parotid gland, and discusses the current diagnosis, treatment and prognosis of NUT carcinoma of the head and neck.

Key words: nuclear protein of the testis carcinoma, head and neck area, parotid gland, diagnosis, prognosis

中图分类号:

R782
R739.

黄金云, 任国欣, 钟薏. 腮腺睾丸核蛋白癌1例病例报告[J]. 《口腔颌面外科杂志》, 2021, 31(3): 196-200.

HUANG Jinyun, REN Guoxin, ZHONG Yi. Nuclear protein of the testis carcinoma of the parotid gland: A case report[J]. 《Journal of Oral and Maxillofacial Surgery》, 2021, 31(3): 196-200.

https://journal06.magtech.org.cn/Jweb_joms/CN/Y2021/V31/I3/196

图/表 2

图1 临床及影像学表现 A. 术后面部侧面像；B. 术后面部正面像；C. 术前MRI增强图像（红色箭头指向肿瘤位置）；D. 术后PET-CT图像（红色箭头指向肿瘤残留位置）。

Figure 1 The clinical and imaging findings

图2 NUT癌组织病理学表现 A. 肿瘤细胞呈巢团状分布（×40）；B. 类似淋巴上皮瘤样癌的结构（×100）；C. 肿瘤细胞细胞核较大，核型多不规则，部分见核仁，偶见核分裂象（×400）；D. NUT（+）（×200）；E. AE1/AE3（部分+）（×200）； F. 鳞状分化瘤细胞 EMA（部分+）（×200）；G. F1i-1（个别+）（×200）；H. FISH检测NUT（+）（×400，肿瘤细胞内见红绿信号分离，提示该基因断裂）。

Figure 2 Histopathology of NUT carcinoma

参考文献 34

[1]	Kees UR, Mulcahy MT, Willoughby ML. Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19)[J]. Am J Pediatr Hematol Oncol, 1991, 13(4): 459-464. doi: 10.1097/00043426-199124000-00011 URL
[2]	French CA. The importance of diagnosing NUT midline carcinoma[J]. Head Neck Pathol, 2013, 7(1): 11-16. doi: 10.1007/s12105-013-0428-1 pmid: 23463074
[3]	Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification[J]. J Thorac Oncol, 2015, 10(9): 1243-1260. doi: S1556-0864(15)33571-1 pmid: 26291008
[4]	French C. NUT midline carcinoma[J]. Nat Rev Cancer, 2014, 14(3): 149-150. doi: 10.1038/nrc3659 pmid: 25688404
[5]	Lee T, Cho J, Baek CH, et al. Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review[J]. Head Neck, 2020, 42(5): 924-938. doi: 10.1002/hed.v42.5 URL
[6]	康婷芳, 赵京, 叶小卫. 鼻咽睾丸核蛋白癌1例并文献回顾[J]. 临床与病理杂志, 2019, 39(1): 227-230.
[7]	徐恩鸿, 张鑫, 纪振华, 等. 鼻腔NUT癌一例[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(10): 778-780.
[8]	Agaimy A, Fonseca I, Martins C, et al. NUT carcinoma of the salivary glands: Clinicopathologic and molecular analysis of 3 cases and a survey of NUT expression in salivary gland carcinomas[J]. Am J Surg Pathol, 2018, 42(7): 877-884. doi: 10.1097/PAS.0000000000001046 pmid: 29649019
[9]	Stelow EB, French CA. Carcinomas of the upper aerodigestive tract with rearrangement of the nuclear protein of the testis(NUT) gene(NUT midline carcinomas)[J]. Adv Anat Pathol, 2009, 16(2): 92-96. doi: 10.1097/PAP.0b013e31819923e4 URL
[10]	Bishop JA, Westra WH. NUT midline carcinomas of the sinonasal tract[J]. Am J Surg Pathol, 2012, 36(8): 1216-1221. doi: 10.1097/PAS.0b013e318254ce54 pmid: 22534723
[11]	French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement[J]. J Clin Oncol, 2004, 22(20): 4135-4139. pmid: 15483023
[12]	Shehata BM, Steelman CK, Abramowsky CR, et al. NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic/hepatic primary[J]. Pediatr Dev Pathol, 2010, 13(6): 481-485. doi: 10.2350/09-10-0727-CR.1 URL
[13]	黄焰, 吴伟, 侯立坤, 等. 肺NUT癌3例临床病理观察[J]. 诊断病理学杂志, 2017, 24(5): 350-353.
[14]	Agaimy A, Fonseca I, Martins C, et al. NUT carcinoma of the salivary glands: Clinicopathologic and molecular analysis of 3 cases and a survey of NUT expression in salivary gland carcinomas[J]. Am J Surg Pathol, 2018, 42(7): 877-884. doi: 10.1097/PAS.0000000000001046 pmid: 29649019
[15]	Stelow EB, Bishop JA. Update from the 4th edition of the World Health Organization classification of head and neck tumours: Tumors of the nasal cavity, paranasal sinuses and skull base[J]. Head Neck Pathol, 2017, 11(1): 3-15. doi: 10.1007/s12105-017-0791-4 pmid: 28247233
[16]	Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification[J]. J Thorac Oncol, 2015, 10(9): 1243-1260. doi: S1556-0864(15)33571-1 pmid: 26291008
[17]	Chau NG, Ma C, Danga K, et al. A novel prognostic risk classification model for NUT midline carcinoma: A largest cohort analysis from the NMC registry[J]. J Clin Oncol, 2018, 36(15_Suppl): 6085. doi: 10.1200/JCO.2018.36.15_suppl.6085 URL
[18]	Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma[J]. Clin Cancer Res, 2012, 18(20): 5773-5779. doi: 10.1158/1078-0432.CCR-12-1153 pmid: 22896655
[19]	Kakkar A, Antony VM, Irugu DVK, et al. NUT midline carcinoma: A series of five cases, including one with unusual clinical course[J]. Head Neck Pathol, 2018, 12(2): 230-236. doi: 10.1007/s12105-017-0858-2 pmid: 28948459
[20]	French CA. Demystified molecular pathology of NUT midline carcinomas[J]. J Clin Pathol, 2010, 63(6): 492-496. doi: 10.1136/jcp.2007.052902 pmid: 18552174
[21]	Rosenbaum DG, Teruya-Feldstein J, Price AP, et al. Radiologic features of NUT midline carcinoma in an adolescent[J]. Pediatr Radiol, 2012, 42(2): 249-252. doi: 10.1007/s00247-011-2288-8 pmid: 22057302
[22]	Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody[J]. Am J Surg Pathol, 2009, 33(7): 984-991. doi: 10.1097/PAS.0b013e318198d666 pmid: 19363441
[23]	Parikh SA, French CA, Costello BA, et al. NUT midline carcinoma: An aggressive intrathoracic neoplasm[J]. J Thorac Oncol, 2013, 8(10): 1335-1338. doi: 10.1097/JTO.0b013e3182a00f41 pmid: 24457244
[24]	Harms A, Herpel E, Pfarr N, et al. NUT carcinoma of the thorax: Case report and review of the literature[J]. Lung Cancer, 2015, 90(3): 484-491. doi: 10.1016/j.lungcan.2015.10.001 pmid: 26490121
[25]	Suzuki S, Kurabe N, Ohnishi I, et al. NSD3-NUT-expressing midline carcinoma of the lung: First characterization of primary cancer tissue[J]. Pathol Res Pract, 2015, 211(5): 404-408. doi: 10.1016/j.prp.2014.10.013 pmid: 25466466
[26]	French CA, Ramirez CL, Kolmakova J, et al. BRD-NUT oncoproteins: A family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells[J]. Oncogene, 2008, 27(15): 2237-2242. doi: 10.1038/sj.onc.1210852 pmid: 17934517
[27]	姜云惠, 袁小星, 柯昌庶. NUT中线癌1例并文献复习[J]. 临床与实验病理学杂志, 2012, 28(11): 1280-1281.
[28]	Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma[J]. Clin Cancer Res, 2012, 18(20): 5773-5779. doi: 10.1158/1078-0432.CCR-12-1153 pmid: 22896655
[29]	Giridhar P, Mallick S, Kashyap L, et al. Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: A systematic review and individual patient data analysis of 119 cases[J]. Eur Arch Otorhinolaryngol, 2018, 275(3): 815-821. doi: 10.1007/s00405-018-4882-y pmid: 29356890
[30]	Edgar M, Caruso AM, Kim E, et al. NUT midline carcinoma of the nasal cavity[J]. Head Neck Pathol, 2017, 11(3): 389-392. doi: 10.1007/s12105-016-0763-0 pmid: 27757815
[31]	Seim NB, Philips RHW, Schoenfield L, et al. NUT midline carcinoma of the sublingual gland: Clinical presentation and review[J]. Head Neck Pathol, 2017, 11(4): 460-468. doi: 10.1007/s12105-017-0809-y pmid: 28349372
[32]	Liao SD, Maertens O, Cichowski K, et al. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is[J]. Genes Dev, 2018, 32(17-18): 1188-1200. doi: 10.1101/gad.315648.118 URL
[33]	Zhu HR, Bengsch F, Svoronos N, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression[J]. Cell Rep, 2016, 16(11): 2829-2837. doi: S2211-1247(16)31096-8 pmid: 27626654
[34]	方微, 刘红刚. 伴有睾丸核蛋白基因重排的中线癌[J]. 中华病理学杂志, 2011, 40(3): 209-212.

选择文件类型/文献管理软件名称

选择包含的内容